Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting

被引:286
作者
Ostrosky-Zeichner, L.
Sable, C.
Sobel, J.
Alexander, B. D.
Donowitz, G.
Kan, V.
Kauffman, C. A.
Kett, D.
Larsen, R. A.
Morrison, V.
Nucci, M.
Pappas, P. G.
Bradley, M. E.
Major, S.
Zimmer, L.
Wallace, D.
Dismukes, W. E.
Rex, J. H.
机构
[1] Univ Texas, Hlth Sci Ctr, Houston, TX 77030 USA
[2] Merck Res Labs, Blue Bell, PA 19422 USA
[3] Wayne State Univ, Brush Ctr 4, Detroit, MI 48201 USA
[4] Duke Univ, Med Ctr, Durham, NC 27710 USA
[5] Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA
[6] Vet Adm Med Ctr, Washington, DC 20422 USA
[7] Univ Michigan, Med Ctr, Ann Arbor, MI 48105 USA
[8] Jackson Mem Hosp, Miami, FL 33136 USA
[9] Univ So Calif, Los Angeles, CA 90033 USA
[10] Vet Adm Med Ctr, Minneapolis, MN 55417 USA
[11] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho Universidade, Rio De Janeiro, Brazil
[12] Univ Alabama, Birmingham, AL 35294 USA
[13] Univ Alabama, Birmingham, AL 35249 USA
[14] Rho, Chapel Hill, NC 27517 USA
[15] AstraZeneca, Macclesfield SK10 4TF, Cheshire, England
关键词
D O I
10.1007/s10096-007-0270-z
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The study presented here was performed in order to create a rule that identifies subjects at high risk for invasive candidiasis in the intensive care setting. Retrospective review and statistical modelling were carried out on 2,890 patients who stayed at least 4 days in nine hospitals in the USA and Brazil; the overall incidence of invasive candidiasis in this group was 3% (88 cases). The best performing rule was as follows: Any systemic antibiotic (days 1-3) OR presence of a central venous catheter (days 1-3) AND at least TWO of the following-total parenteral nutrition (days 1-3), any dialysis (days 1-3), any major surgery (days -7-0), pancreatitis (days -7-0), any use of steroids (days -7-3), or use of other immunosuppressive agents (days -7-0). The rate of invasive candidiasis among patients meeting the rule was 9.9%, capturing 34% of cases in the units, with the following performance: relative risk 4.36, sensitivity 0.34, specificity 0.90, positive predictive value 0.01, and negative predictive value 0.97. The rule may identify patients at high risk of invasive candidiasis.
引用
收藏
页码:271 / 276
页数:6
相关论文
共 14 条
[1]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[2]   Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS Prospective Multicenter Study [J].
Blumberg, HM ;
Jarvis, WR ;
Soucie, JM ;
Edwards, JE ;
Patterson, JE ;
Pfaller, MA ;
Rangel-Frausto, MS ;
Rinaldi, MG ;
Saiman, L ;
Wiblin, RT ;
Wenzel, RP .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) :177-186
[3]   Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? [J].
Dupont, H ;
Bourichon, A ;
Paugam-Burtz, C ;
Mantz, J ;
Desmonts, JM .
CRITICAL CARE MEDICINE, 2003, 31 (03) :752-757
[4]   Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients [J].
Eggimann, P ;
Francioli, P ;
Bille, J ;
Schneider, R ;
Wu, MM ;
Chapuis, G ;
Chiolero, R ;
Pannatier, A ;
Schilling, J ;
Geroulanos, S ;
Glauser, MP ;
Calandra, T .
CRITICAL CARE MEDICINE, 1999, 27 (06) :1066-1072
[5]   Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients:: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination [J].
Garbino, J ;
Lew, DP ;
Romand, JA ;
Hugonnet, S ;
Auckenthaler, R ;
Pittet, D .
INTENSIVE CARE MEDICINE, 2002, 28 (12) :1708-1717
[6]   Attributable mortality of nosocomial candidemia, revisited [J].
Gudlaugsson, O ;
Gillespie, S ;
Lee, K ;
Berg, JV ;
Hu, JF ;
Messer, S ;
Herwaldt, L ;
Pfaller, M ;
Diekema, D .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) :1172-1177
[7]   A bedside scoring system ("Candida score'') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization [J].
León, C ;
Ruiz-Santana, S ;
Saavedra, P ;
Almirante, B ;
Nolla-Salas, J ;
Alvarez-Lerma, F ;
Garnacho-Montero, J ;
León, MA .
CRITICAL CARE MEDICINE, 2006, 34 (03) :730-737
[8]   Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials [J].
Paphitou, NI ;
Ostrosky-Zeichner, L ;
Rex, JH .
MEDICAL MYCOLOGY, 2005, 43 (03) :235-243
[9]   Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients [J].
Pelz, RK ;
Hendrix, CW ;
Swoboda, SM ;
Diener-West, M ;
Merz, WG ;
Hammond, J ;
Lipsett, PA .
ANNALS OF SURGERY, 2001, 233 (04) :542-548
[10]   Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients [J].
Piarroux, R ;
Grenouillet, F ;
Balvay, P ;
Tran, W ;
Blasco, G ;
Millon, L ;
Boillot, A .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2443-2449